Table of Content

1 Report Overview
1.1 Choroidal Neovascularization Drug Definition
1.2 Market by Type
1.2.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 AVMOC-001
1.2.3 BB-3
1.2.4 BBT-007
1.2.5 DG-3
1.2.6 Entolimod
1.2.7 EWA-001
1.2.8 Others
1.3 Market Segment by Application
1.3.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Choroidal Neovascularization Drug Sales
2.1 Global Choroidal Neovascularization Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Choroidal Neovascularization Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Choroidal Neovascularization Drug Revenue by Region
2.3.1 Global Choroidal Neovascularization Drug Revenue by Region (2018-2023)
2.3.2 Global Choroidal Neovascularization Drug Revenue by Region (2024-2034)
2.4 Global Choroidal Neovascularization Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Choroidal Neovascularization Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Choroidal Neovascularization Drug Sales Quantity by Region
2.6.1 Global Choroidal Neovascularization Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Choroidal Neovascularization Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Choroidal Neovascularization Drug Sales Quantity by Manufacturers
3.1.1 Global Choroidal Neovascularization Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Choroidal Neovascularization Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Choroidal Neovascularization Drug Sales in 2024
3.2 Global Choroidal Neovascularization Drug Revenue by Manufacturers
3.2.1 Global Choroidal Neovascularization Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Choroidal Neovascularization Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Choroidal Neovascularization Drug Revenue in 2024
3.3 Global Choroidal Neovascularization Drug Sales Price by Manufacturers
3.4 Global Key Players of Choroidal Neovascularization Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Choroidal Neovascularization Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Choroidal Neovascularization Drug, Product Offered and Application
3.8 Global Key Manufacturers of Choroidal Neovascularization Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Choroidal Neovascularization Drug Sales Quantity by Type
4.1.1 Global Choroidal Neovascularization Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Choroidal Neovascularization Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Choroidal Neovascularization Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Choroidal Neovascularization Drug Revenue by Type
4.2.1 Global Choroidal Neovascularization Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Choroidal Neovascularization Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2018-2034)
4.3 Global Choroidal Neovascularization Drug Price by Type
4.3.1 Global Choroidal Neovascularization Drug Price by Type (2018-2023)
4.3.2 Global Choroidal Neovascularization Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Choroidal Neovascularization Drug Sales Quantity by Application
5.1.1 Global Choroidal Neovascularization Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Choroidal Neovascularization Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Choroidal Neovascularization Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Choroidal Neovascularization Drug Revenue by Application
5.2.1 Global Choroidal Neovascularization Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Choroidal Neovascularization Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2018-2034)
5.3 Global Choroidal Neovascularization Drug Price by Application
5.3.1 Global Choroidal Neovascularization Drug Price by Application (2018-2023)
5.3.2 Global Choroidal Neovascularization Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Choroidal Neovascularization Drug Sales by Company
6.1.1 North America Choroidal Neovascularization Drug Revenue by Company (2018-2023)
6.1.2 North America Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023)
6.2 North America Choroidal Neovascularization Drug Market Size by Type
6.2.1 North America Choroidal Neovascularization Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Choroidal Neovascularization Drug Revenue by Type (2018-2034)
6.3 North America Choroidal Neovascularization Drug Market Size by Application
6.3.1 North America Choroidal Neovascularization Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Choroidal Neovascularization Drug Revenue by Application (2018-2034)
6.4 North America Choroidal Neovascularization Drug Market Size by Country
6.4.1 North America Choroidal Neovascularization Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Choroidal Neovascularization Drug Revenue by Country (2018-2034)
6.4.3 North America Choroidal Neovascularization Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Choroidal Neovascularization Drug Sales by Company
7.1.1 Europe Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Choroidal Neovascularization Drug Revenue by Company (2018-2023)
7.2 Europe Choroidal Neovascularization Drug Market Size by Type
7.2.1 Europe Choroidal Neovascularization Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Choroidal Neovascularization Drug Revenue by Type (2018-2034)
7.3 Europe Choroidal Neovascularization Drug Market Size by Application
7.3.1 Europe Choroidal Neovascularization Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Choroidal Neovascularization Drug Revenue by Application (2018-2034)
7.4 Europe Choroidal Neovascularization Drug Market Size by Country
7.4.1 Europe Choroidal Neovascularization Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Choroidal Neovascularization Drug Revenue by Country (2018-2034)
7.4.3 Europe Choroidal Neovascularization Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Choroidal Neovascularization Drug Sales by Company
8.1.1 China Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023)
8.1.2 China Choroidal Neovascularization Drug Revenue by Company (2018-2023)
8.2 China Choroidal Neovascularization Drug Market Size by Type
8.2.1 China Choroidal Neovascularization Drug Sales Quantity by Type (2018-2034)
8.2.2 China Choroidal Neovascularization Drug Revenue by Type (2018-2034)
8.3 China Choroidal Neovascularization Drug Market Size by Application
8.3.1 China Choroidal Neovascularization Drug Sales Quantity by Application (2018-2034)
8.3.2 China Choroidal Neovascularization Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Choroidal Neovascularization Drug Sales by Company
9.1.1 APAC Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Choroidal Neovascularization Drug Revenue by Company (2018-2023)
9.2 APAC Choroidal Neovascularization Drug Market Size by Type
9.2.1 APAC Choroidal Neovascularization Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Choroidal Neovascularization Drug Revenue by Type (2018-2034)
9.3 APAC Choroidal Neovascularization Drug Market Size by Application
9.3.1 APAC Choroidal Neovascularization Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Choroidal Neovascularization Drug Revenue by Application (2018-2034)
9.4 APAC Choroidal Neovascularization Drug Market Size by Region
9.4.1 APAC Choroidal Neovascularization Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Choroidal Neovascularization Drug Revenue by Region (2018-2034)
9.4.3 APAC Choroidal Neovascularization Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Choroidal Neovascularization Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Choroidal Neovascularization Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Choroidal Neovascularization Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Cellphire, Inc.
11.1.1 Cellphire, Inc. Company Information
11.1.2 Cellphire, Inc. Overview
11.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Products and Services
11.1.5 Cellphire, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.1.6 Cellphire, Inc. Recent Developments
11.2 Chrysalis BioTherapeutics, Inc.
11.2.1 Chrysalis BioTherapeutics, Inc. Company Information
11.2.2 Chrysalis BioTherapeutics, Inc. Overview
11.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.2.5 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.2.6 Chrysalis BioTherapeutics, Inc. Recent Developments
11.3 Cleveland BioLabs, Inc.
11.3.1 Cleveland BioLabs, Inc. Company Information
11.3.2 Cleveland BioLabs, Inc. Overview
11.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Products and Services
11.3.5 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.3.6 Cleveland BioLabs, Inc. Recent Developments
11.4 Cumberland Pharmaceuticals, Inc.
11.4.1 Cumberland Pharmaceuticals, Inc. Company Information
11.4.2 Cumberland Pharmaceuticals, Inc. Overview
11.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Products and Services
11.4.5 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.4.6 Cumberland Pharmaceuticals, Inc. Recent Developments
11.5 Diffusion Pharmaceuticals Inc.
11.5.1 Diffusion Pharmaceuticals Inc. Company Information
11.5.2 Diffusion Pharmaceuticals Inc. Overview
11.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Products and Services
11.5.5 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug SWOT Analysis
11.5.6 Diffusion Pharmaceuticals Inc. Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Information
11.6.2 Eli Lilly and Company Overview
11.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Products and Services
11.6.5 Eli Lilly and Company Choroidal Neovascularization Drug SWOT Analysis
11.6.6 Eli Lilly and Company Recent Developments
11.7 GNI Group Ltd.
11.7.1 GNI Group Ltd. Company Information
11.7.2 GNI Group Ltd. Overview
11.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Products and Services
11.7.5 GNI Group Ltd. Choroidal Neovascularization Drug SWOT Analysis
11.7.6 GNI Group Ltd. Recent Developments
11.8 Humanetics Corporation
11.8.1 Humanetics Corporation Company Information
11.8.2 Humanetics Corporation Overview
11.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Humanetics Corporation Choroidal Neovascularization Drug Products and Services
11.8.5 Humanetics Corporation Choroidal Neovascularization Drug SWOT Analysis
11.8.6 Humanetics Corporation Recent Developments
11.9 INSYS Therapeutics, Inc.
11.9.1 INSYS Therapeutics, Inc. Company Information
11.9.2 INSYS Therapeutics, Inc. Overview
11.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.9.5 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
11.9.6 INSYS Therapeutics, Inc. Recent Developments
11.10 Meabco A/S
11.10.1 Meabco A/S Company Information
11.10.2 Meabco A/S Overview
11.10.3 Meabco A/S Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Meabco A/S Choroidal Neovascularization Drug Products and Services
11.10.5 Meabco A/S Choroidal Neovascularization Drug SWOT Analysis
11.10.6 Meabco A/S Recent Developments
11.11 Neumedicines Inc.
11.11.1 Neumedicines Inc. Company Information
11.11.2 Neumedicines Inc. Overview
11.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Neumedicines Inc. Choroidal Neovascularization Drug Products and Services
11.11.5 Neumedicines Inc. Recent Developments
11.12 Onconova Therapeutics, Inc.
11.12.1 Onconova Therapeutics, Inc. Company Information
11.12.2 Onconova Therapeutics, Inc. Overview
11.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Products and Services
11.12.5 Onconova Therapeutics, Inc. Recent Developments
11.13 PharmaIN Corporation
11.13.1 PharmaIN Corporation Company Information
11.13.2 PharmaIN Corporation Overview
11.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 PharmaIN Corporation Choroidal Neovascularization Drug Products and Services
11.13.5 PharmaIN Corporation Recent Developments
11.14 Pluristem Therapeutics Inc.
11.14.1 Pluristem Therapeutics Inc. Company Information
11.14.2 Pluristem Therapeutics Inc. Overview
11.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Products and Services
11.14.5 Pluristem Therapeutics Inc. Recent Developments
11.15 ProCertus BioPharm Inc.
11.15.1 ProCertus BioPharm Inc. Company Information
11.15.2 ProCertus BioPharm Inc. Overview
11.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Products and Services
11.15.5 ProCertus BioPharm Inc. Recent Developments
11.16 RDD Pharma Ltd.
11.16.1 RDD Pharma Ltd. Company Information
11.16.2 RDD Pharma Ltd. Overview
11.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Products and Services
11.16.5 RDD Pharma Ltd. Recent Developments
11.17 RedHill Biopharma Ltd.
11.17.1 RedHill Biopharma Ltd. Company Information
11.17.2 RedHill Biopharma Ltd. Overview
11.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Products and Services
11.17.5 RedHill Biopharma Ltd. Recent Developments
11.18 RxBio, Inc.
11.18.1 RxBio, Inc. Company Information
11.18.2 RxBio, Inc. Overview
11.18.3 RxBio, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 RxBio, Inc. Choroidal Neovascularization Drug Products and Services
11.18.5 RxBio, Inc. Recent Developments
11.19 Soligenix, Inc.
11.19.1 Soligenix, Inc. Company Information
11.19.2 Soligenix, Inc. Overview
11.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.19.4 Soligenix, Inc. Choroidal Neovascularization Drug Products and Services
11.19.5 Soligenix, Inc. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Choroidal Neovascularization Drug Value Chain Analysis
12.2 Choroidal Neovascularization Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Choroidal Neovascularization Drug Production Mode & Process
12.4 Choroidal Neovascularization Drug Sales and Marketing
12.4.1 Choroidal Neovascularization Drug Sales Channels
12.4.2 Choroidal Neovascularization Drug Distributors
12.5 Choroidal Neovascularization Drug Customers
13 Market Dynamics
13.1 Choroidal Neovascularization Drug Industry Trends
13.2 Choroidal Neovascularization Drug Market Drivers
13.3 Choroidal Neovascularization Drug Market Challenges
13.4 Choroidal Neovascularization Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of AVMOC-001
Table 3. Major Manufacturers of BB-3
Table 4. Major Manufacturers of BBT-007
Table 5. Major Manufacturers of DG-3
Table 6. Major Manufacturers of Entolimod
Table 7. Major Manufacturers of EWA-001
Table 8. Major Manufacturers of Others
Table 9. Global Choroidal Neovascularization Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Choroidal Neovascularization Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global Choroidal Neovascularization Drug Revenue by Region (2018-2023) & (US$ Million)
Table 12. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2018-2023)
Table 13. Global Choroidal Neovascularization Drug Revenue by Region (2024-2034) & (US$ Million)
Table 14. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2024-2034)
Table 15. Global Choroidal Neovascularization Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 16. Global Choroidal Neovascularization Drug Sales by Region (2018-2023) & (K Pcs)
Table 17. Global Choroidal Neovascularization Drug Sales Market Share by Region (2018-2023)
Table 18. Global Choroidal Neovascularization Drug Sales by Region (2024-2034) & (K Pcs)
Table 19. Global Choroidal Neovascularization Drug Sales Market Share by Region (2024-2034)
Table 20. Global Choroidal Neovascularization Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 21. Global Choroidal Neovascularization Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 22. Global Choroidal Neovascularization Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 23. Global Choroidal Neovascularization Drug Revenue Share by Manufacturers (2018-2023)
Table 24. Global Choroidal Neovascularization Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 25. Global Key Players of Choroidal Neovascularization Drug, Industry Ranking, 2021 VS 2024
Table 26. Global Choroidal Neovascularization Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global Choroidal Neovascularization Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Choroidal Neovascularization Drug as of 2024)
Table 28. Global Key Manufacturers of Choroidal Neovascularization Drug, Manufacturing Base Distribution and Headquarters
Table 29. Global Key Manufacturers of Choroidal Neovascularization Drug, Product Offered and Application
Table 30. Global Key Manufacturers of Choroidal Neovascularization Drug, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Choroidal Neovascularization Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 33. Global Choroidal Neovascularization Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 34. Global Choroidal Neovascularization Drug Sales Quantity Share by Type (2018-2023)
Table 35. Global Choroidal Neovascularization Drug Sales Quantity Share by Type (2024-2034)
Table 36. Global Choroidal Neovascularization Drug Revenue by Type (2018-2023) & (US$ Million)
Table 37. Global Choroidal Neovascularization Drug Revenue by Type (2024-2034) & (US$ Million)
Table 38. Global Choroidal Neovascularization Drug Revenue Share by Type (2018-2023)
Table 39. Global Choroidal Neovascularization Drug Revenue Share by Type (2024-2034)
Table 40. Choroidal Neovascularization Drug Price by Type (2018-2023) & (USD/Pcs)
Table 41. Global Choroidal Neovascularization Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 42. Global Choroidal Neovascularization Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 43. Global Choroidal Neovascularization Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 44. Global Choroidal Neovascularization Drug Sales Quantity Share by Application (2018-2023)
Table 45. Global Choroidal Neovascularization Drug Sales Quantity Share by Application (2024-2034)
Table 46. Global Choroidal Neovascularization Drug Revenue by Application (2018-2023) & (US$ Million)
Table 47. Global Choroidal Neovascularization Drug Revenue by Application (2024-2034) & (US$ Million)
Table 48. Global Choroidal Neovascularization Drug Revenue Share by Application (2018-2023)
Table 49. Global Choroidal Neovascularization Drug Revenue Share by Application (2024-2034)
Table 50. Choroidal Neovascularization Drug Price by Application (2018-2023) & (USD/Pcs)
Table 51. Global Choroidal Neovascularization Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 52. North America Choroidal Neovascularization Drug Revenue by Company (2018-2023) & (US$ Million)
Table 53. North America Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 54. North America Choroidal Neovascularization Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 55. North America Choroidal Neovascularization Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 56. North America Choroidal Neovascularization Drug Revenue by Type (2018-2023) & (US$ Million)
Table 57. North America Choroidal Neovascularization Drug Revenue by Type (2024-2034) & (US$ Million)
Table 58. North America Choroidal Neovascularization Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 59. North America Choroidal Neovascularization Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 60. North America Choroidal Neovascularization Drug Revenue by Application (2018-2023) & (US$ Million)
Table 61. North America Choroidal Neovascularization Drug Revenue by Application (2024-2034) & (US$ Million)
Table 62. North America Choroidal Neovascularization Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 63. North America Choroidal Neovascularization Drug Revenue by Country (2018-2023) & (US$ Million)
Table 64. North America Choroidal Neovascularization Drug Revenue by Country (2024-2034) & (US$ Million)
Table 65. North America Choroidal Neovascularization Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 66. North America Choroidal Neovascularization Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 67. Europe Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 68. Europe Choroidal Neovascularization Drug Revenue by Company (2018-2023) & (US$ Million)
Table 69. Europe Choroidal Neovascularization Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 70. Europe Choroidal Neovascularization Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 71. Europe Choroidal Neovascularization Drug Revenue by Type (2018-2023) & (US$ Million)
Table 72. Europe Choroidal Neovascularization Drug Revenue by Type (2024-2034) & (US$ Million)
Table 73. Europe Choroidal Neovascularization Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 74. Europe Choroidal Neovascularization Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 75. Europe Choroidal Neovascularization Drug Revenue by Application (2018-2023) & (US$ Million)
Table 76. Europe Choroidal Neovascularization Drug Revenue by Application (2024-2034) & (US$ Million)
Table 77. Europe Choroidal Neovascularization Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 78. Europe Choroidal Neovascularization Drug Revenue by Country (2018-2023) & (US$ Million)
Table 79. Europe Choroidal Neovascularization Drug Revenue by Country (2024-2034) & (US$ Million)
Table 80. Europe Choroidal Neovascularization Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 81. Europe Choroidal Neovascularization Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 82. China Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 83. China Choroidal Neovascularization Drug Revenue by Company (2018-2023) & (US$ Million)
Table 84. China Choroidal Neovascularization Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 85. China Choroidal Neovascularization Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 86. China Choroidal Neovascularization Drug Revenue by Type (2018-2023) & (US$ Million)
Table 87. China Choroidal Neovascularization Drug Revenue by Type (2024-2034) & (US$ Million)
Table 88. China Choroidal Neovascularization Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 89. China Choroidal Neovascularization Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 90. China Choroidal Neovascularization Drug Revenue by Application (2018-2023) & (US$ Million)
Table 91. China Choroidal Neovascularization Drug Revenue by Application (2024-2034) & (US$ Million)
Table 92. APAC Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 93. APAC Choroidal Neovascularization Drug Revenue by Company (2018-2023) & (US$ Million)
Table 94. APAC Choroidal Neovascularization Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 95. APAC Choroidal Neovascularization Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 96. APAC Choroidal Neovascularization Drug Revenue by Type (2018-2023) & (US$ Million)
Table 97. APAC Choroidal Neovascularization Drug Revenue by Type (2024-2034) & (US$ Million)
Table 98. APAC Choroidal Neovascularization Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 99. APAC Choroidal Neovascularization Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 100. APAC Choroidal Neovascularization Drug Revenue by Application (2018-2023) & (US$ Million)
Table 101. APAC Choroidal Neovascularization Drug Revenue by Application (2024-2034) & (US$ Million)
Table 102. APAC Choroidal Neovascularization Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 103. APAC Choroidal Neovascularization Drug Revenue by Region (2018-2023) & (US$ Million)
Table 104. APAC Choroidal Neovascularization Drug Revenue by Region (2024-2034) & (US$ Million)
Table 105. APAC Choroidal Neovascularization Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 106. APAC Choroidal Neovascularization Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 107. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 108. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Company (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 110. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 111. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Type (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Type (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 114. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 115. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Application (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Application (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 118. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Country (2018-2023) & (US$ Million)
Table 119. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue by Country (2024-2034) & (US$ Million)
Table 120. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 121. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 122. Cellphire, Inc. Company Information
Table 123. Cellphire, Inc. Description and Overview
Table 124. Cellphire, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 125. Cellphire, Inc. Choroidal Neovascularization Drug Product and Services
Table 126. Cellphire, Inc. Choroidal Neovascularization Drug SWOT Analysis
Table 127. Cellphire, Inc. Recent Developments
Table 128. Chrysalis BioTherapeutics, Inc. Company Information
Table 129. Chrysalis BioTherapeutics, Inc. Description and Overview
Table 130. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 131. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 132. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
Table 133. Chrysalis BioTherapeutics, Inc. Recent Developments
Table 134. Cleveland BioLabs, Inc. Company Information
Table 135. Cleveland BioLabs, Inc. Description and Overview
Table 136. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 137. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product and Services
Table 138. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug SWOT Analysis
Table 139. Cleveland BioLabs, Inc. Recent Developments
Table 140. Cumberland Pharmaceuticals, Inc. Company Information
Table 141. Cumberland Pharmaceuticals, Inc. Description and Overview
Table 142. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 143. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product and Services
Table 144. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug SWOT Analysis
Table 145. Cumberland Pharmaceuticals, Inc. Recent Developments
Table 146. Diffusion Pharmaceuticals Inc. Company Information
Table 147. Diffusion Pharmaceuticals Inc. Description and Overview
Table 148. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 149. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product and Services
Table 150. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug SWOT Analysis
Table 151. Diffusion Pharmaceuticals Inc. Recent Developments
Table 152. Eli Lilly and Company Company Information
Table 153. Eli Lilly and Company Description and Overview
Table 154. Eli Lilly and Company Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 155. Eli Lilly and Company Choroidal Neovascularization Drug Product and Services
Table 156. Eli Lilly and Company Choroidal Neovascularization Drug SWOT Analysis
Table 157. Eli Lilly and Company Recent Developments
Table 158. GNI Group Ltd. Company Information
Table 159. GNI Group Ltd. Description and Overview
Table 160. GNI Group Ltd. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 161. GNI Group Ltd. Choroidal Neovascularization Drug Product and Services
Table 162. GNI Group Ltd. Choroidal Neovascularization Drug SWOT Analysis
Table 163. GNI Group Ltd. Recent Developments
Table 164. Humanetics Corporation Company Information
Table 165. Humanetics Corporation Description and Overview
Table 166. Humanetics Corporation Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 167. Humanetics Corporation Choroidal Neovascularization Drug Product and Services
Table 168. Humanetics Corporation Choroidal Neovascularization Drug SWOT Analysis
Table 169. Humanetics Corporation Recent Developments
Table 170. INSYS Therapeutics, Inc. Company Information
Table 171. INSYS Therapeutics, Inc. Description and Overview
Table 172. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 173. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 174. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug SWOT Analysis
Table 175. INSYS Therapeutics, Inc. Recent Developments
Table 176. Meabco A/S Company Information
Table 177. Meabco A/S Description and Overview
Table 178. Meabco A/S Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 179. Meabco A/S Choroidal Neovascularization Drug Product and Services
Table 180. Meabco A/S Choroidal Neovascularization Drug SWOT Analysis
Table 181. Meabco A/S Recent Developments
Table 182. Neumedicines Inc. Company Information
Table 183. Neumedicines Inc. Description and Overview
Table 184. Neumedicines Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 185. Neumedicines Inc. Choroidal Neovascularization Drug Product and Services
Table 186. Neumedicines Inc. Recent Developments
Table 187. Onconova Therapeutics, Inc. Company Information
Table 188. Onconova Therapeutics, Inc. Description and Overview
Table 189. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 190. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 191. Onconova Therapeutics, Inc. Recent Developments
Table 192. PharmaIN Corporation Company Information
Table 193. PharmaIN Corporation Description and Overview
Table 194. PharmaIN Corporation Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 195. PharmaIN Corporation Choroidal Neovascularization Drug Product and Services
Table 196. PharmaIN Corporation Recent Developments
Table 197. Pluristem Therapeutics Inc. Company Information
Table 198. Pluristem Therapeutics Inc. Description and Overview
Table 199. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 200. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product and Services
Table 201. Pluristem Therapeutics Inc. Recent Developments
Table 202. ProCertus BioPharm Inc. Company Information
Table 203. ProCertus BioPharm Inc. Description and Overview
Table 204. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 205. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product and Services
Table 206. ProCertus BioPharm Inc. Recent Developments
Table 207. RDD Pharma Ltd. Company Information
Table 208. RDD Pharma Ltd. Description and Overview
Table 209. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 210. RDD Pharma Ltd. Choroidal Neovascularization Drug Product and Services
Table 211. RDD Pharma Ltd. Recent Developments
Table 212. RedHill Biopharma Ltd. Company Information
Table 213. RedHill Biopharma Ltd. Description and Overview
Table 214. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 215. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product and Services
Table 216. RedHill Biopharma Ltd. Recent Developments
Table 217. RxBio, Inc. Company Information
Table 218. RxBio, Inc. Description and Overview
Table 219. RxBio, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 220. RxBio, Inc. Choroidal Neovascularization Drug Product and Services
Table 221. RxBio, Inc. Recent Developments
Table 222. Soligenix, Inc. Company Information
Table 223. Soligenix, Inc. Description and Overview
Table 224. Soligenix, Inc. Choroidal Neovascularization Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 225. Soligenix, Inc. Choroidal Neovascularization Drug Product and Services
Table 226. Soligenix, Inc. Recent Developments
Table 227. Key Raw Materials Lists
Table 228. Raw Materials Key Suppliers Lists
Table 229. Choroidal Neovascularization Drug Distributors List
Table 230. Choroidal Neovascularization Drug Customers List
Table 231. Choroidal Neovascularization Drug Market Trends
Table 232. Choroidal Neovascularization Drug Market Drivers
Table 233. Choroidal Neovascularization Drug Market Challenges
Table 234. Choroidal Neovascularization Drug Market Restraints
Table 235. Research Programs/Design for This Report
Table 236. Key Data Information from Secondary Sources
Table 237. Key Data Information from Primary Sources
List of Figures
Figure 1. Choroidal Neovascularization Drug Product Picture
Figure 2. Global Choroidal Neovascularization Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Choroidal Neovascularization Drug Market Share by Type in 2024 & 2034
Figure 4. AVMOC-001 Product Picture
Figure 5. BB-3 Product Picture
Figure 6. BBT-007 Product Picture
Figure 7. DG-3 Product Picture
Figure 8. Entolimod Product Picture
Figure 9. EWA-001 Product Picture
Figure 10. Others Product Picture
Figure 11. Global Choroidal Neovascularization Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 12. Global Choroidal Neovascularization Drug Market Share by Application in 2024 & 2034
Figure 13. Clinic
Figure 14. Hospital
Figure 15. Others
Figure 16. Choroidal Neovascularization Drug Report Years Considered
Figure 17. Global Choroidal Neovascularization Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 18. Global Choroidal Neovascularization Drug Revenue 2018-2034 (US$ Million)
Figure 19. Global Choroidal Neovascularization Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 20. Global Choroidal Neovascularization Drug Sales Quantity 2018-2034 (K Pcs)
Figure 21. Global Choroidal Neovascularization Drug Sales Quantity Market Share by Region (2018-2023)
Figure 22. Global Choroidal Neovascularization Drug Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Choroidal Neovascularization Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. North America Choroidal Neovascularization Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Choroidal Neovascularization Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. Europe Choroidal Neovascularization Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Choroidal Neovascularization Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. China Choroidal Neovascularization Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Choroidal Neovascularization Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. APAC Choroidal Neovascularization Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 32. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Choroidal Neovascularization Drug Sales Quantity in 2024
Figure 34. The Top 10 and Top 5 Players Market Share by Choroidal Neovascularization Drug Revenue in 2024
Figure 35. Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 36. Global Choroidal Neovascularization Drug Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2018-2034)
Figure 38. Global Choroidal Neovascularization Drug Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2018-2034)
Figure 40. North America Choroidal Neovascularization Drug Revenue Market Share by Company in 2024
Figure 41. North America Choroidal Neovascularization Drug Sales Quantity Market Share by Company in 2024
Figure 42. North America Choroidal Neovascularization Drug Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Choroidal Neovascularization Drug Revenue Market Share by Type (2018-2034)
Figure 44. North America Choroidal Neovascularization Drug Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Choroidal Neovascularization Drug Revenue Market Share by Application (2018-2034)
Figure 46. North America Choroidal Neovascularization Drug Revenue Share by Country (2018-2034)
Figure 47. North America Choroidal Neovascularization Drug Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Choroidal Neovascularization Drug Sales Quantity Market Share by Company in 2024
Figure 51. Europe Choroidal Neovascularization Drug Revenue Market Share by Company in 2024
Figure 52. Europe Choroidal Neovascularization Drug Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Choroidal Neovascularization Drug Revenue Market Share by Type (2018-2034)
Figure 54. Europe Choroidal Neovascularization Drug Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Choroidal Neovascularization Drug Revenue Market Share by Application (2018-2034)
Figure 56. Europe Choroidal Neovascularization Drug Revenue Share by Country (2018-2034)
Figure 57. Europe Choroidal Neovascularization Drug Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 59. France Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 63. China Choroidal Neovascularization Drug Sales Quantity Market Share by Company in 2024
Figure 64. China Choroidal Neovascularization Drug Revenue Market Share by Company in 2024
Figure 65. China Choroidal Neovascularization Drug Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Choroidal Neovascularization Drug Revenue Market Share by Type (2018-2034)
Figure 67. China Choroidal Neovascularization Drug Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Choroidal Neovascularization Drug Revenue Market Share by Application (2018-2034)
Figure 69. APAC Choroidal Neovascularization Drug Sales Quantity Market Share by Company in 2024
Figure 70. APAC Choroidal Neovascularization Drug Revenue Market Share by Company in 2024
Figure 71. APAC Choroidal Neovascularization Drug Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Choroidal Neovascularization Drug Revenue Market Share by Type (2018-2034)
Figure 73. APAC Choroidal Neovascularization Drug Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Choroidal Neovascularization Drug Revenue Market Share by Application (2018-2034)
Figure 75. APAC Choroidal Neovascularization Drug Revenue Share by Region (2018-2034)
Figure 76. APAC Choroidal Neovascularization Drug Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 81. India Choroidal Neovascularization Drug Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Choroidal Neovascularization Drug Sales Quantity Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Choroidal Neovascularization Drug Revenue Market Shar